newsfilter
← Latest News
GlobeNewswire·

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesionsBased on the favorable safety and tolerability data at all doses tested to date, the Company